ABBOTT LABORATORIESABT
ABBOTT LABORATORIES Financial Overview 2021–2025
Updated Jul 10, 2026Abbott Laboratories' $20.6 billion acquisition of Exact Sciences in Q1 2026 signals a definitive end to its pandemic-era identity. By issuing $20 billion in debt to capture the cancer diagnostics market, the company proved it is aggressively pivoting toward its next wave of structural expansion. The core investment thesis is clear: despite a multi-year secular drag from vanishing COVID-19 test revenue, Abbott’s underlying Medical Devices portfolio—anchored by continuous glucose monitors—has consistently driven the business back to sustainable, organic growth.
Navigating the post-pandemic hangover required a massive internal rotation, reflected in how earnings per share contracted from the testing-fueled peak of $3.94 in FY2021 to a more normalized $3.72 in FY2025. Over that span, the company absorbed severe headwinds, including a 63.3% drop in Rapid Diagnostics sales in FY2023 and a volatile U.S. infant formula recall. Yet, Abbott successfully replaced those lost revenues with core medical technology sales, pushing total net sales to $44.3 billion in FY2025. The Medical Devices segment experienced 12.6% growth that year, supercharged by its FreeStyle Libre diabetes franchise, which generated $6.4 billion in sales during FY2024. The market has largely rewarded this successful transition away from pandemic windfalls; at the close of FY2025, Abbott traded at 33.7x earnings with a share price of $125.29.
Recent Developments (Q4 2025 and Q1 2026)
Following a solid close to Q4 2025, Abbott’s Q1 2026 performance revealed the immediate margin pressure of its recent strategic shift. Total net sales jumped 7.8% year-over-year to $11.164 billion, bolstered by a 13.2% surge in Established Pharmaceuticals. However, net earnings dropped to $1.077 billion. This reduced diluted EPS to $0.61 from $0.76 in the prior year due to higher operating and interest costs from integrating its new cancer diagnostics division. Total long-term debt now stands at $29.638 billion.
In April, the company secured preliminary court approval to settle its infant formula shareholder derivative litigation. Bulls will argue that robust top-line momentum and a 6.8% dividend hike to $0.63 per share demonstrate resilient cash generation. Conversely, bears warn that sliding Nutritional Products sales, which fell 6.0%, alongside elevated debt servicing will compress near-term profitability. After a recent price pullback, the stock appears cheaply valued, trading at 24.6x earnings at $91.33 as of the April 29, 2026 reporting date.
What to watch: margin stabilization as integration costs normalize; finalization of the infant formula litigation settlement.
Rev
$44.33B
FY2025
NI
$6.52B
FY2025
EPS
$3.73
FY2025
OCF
$9.57B
FY2025
Year-over-year comparison from 10-K annual reports
Data from SEC Company Facts
Recent SEC Filings
ABBOTT LABORATORIES 8-K Report, Executive Changes (Apr 27, 2026)
Abbott Laboratories (ABT) announced significant corporate governance updates following its Annual Shareholder Meeting on April 24, 2026. A key development is the approval of the Abbott Laboratories 2026 Incentive Stock Program, which will replace the previous 2017 program. This new program allows for a broad range of equity-based awards to employees and non-employee directors, with a maximum of 140,000,000 shares available, plus additional shares from the prior program's unused reserves. The program's adoption was overwhelmingly approved by shareholders, indicating strong support for the company's long-term incentive strategy. Additionally, the Board of Directors has been expanded from twelve to thirteen members, effective April 24, 2026. Shareholders also re-elected the entire slate of directors and ratified the appointment of Ernst & Young LLP as the company's auditors. The compensation of named executive officers was approved in an advisory vote, reflecting shareholder confidence in management's remuneration practices. These changes underscore Abbott's commitment to robust governance and aligning executive incentives with shareholder interests.
ABBOTT LABORATORIES 8-K Report, Corporate Update (Apr 17, 2026)
Abbott Laboratories has filed an 8-K report on April 17, 2026, announcing a significant development in a consolidated shareholder derivative lawsuit, "In re Abbott Laboratories Infant Formula Shareholder Derivative Litigation." The company's filing indicates that on April 10, 2026, the court preliminarily approved a proposed settlement in this long-standing litigation concerning certain current and former directors and officers. This preliminary approval is a crucial step towards resolving the six shareholder derivative lawsuits that have been consolidated. While the settlement is not yet final and a final settlement hearing will be scheduled, this development suggests a potential resolution to a significant legal overhang. Investors should note that further details regarding the terms of the settlement will be available in the "Notice of Proposed Settlement of Consolidated Derivative Action, Final Settlement Hearing, and Right to Appear," which is filed as an exhibit to this report. This filing is important for understanding potential legal liabilities and corporate governance matters at Abbott.
ABBOTT LABORATORIES 8-K Report, Financial Results (Apr 16, 2026)
Abbott Laboratories (ABT) has filed an 8-K report on April 16, 2026, to announce its financial results for the first quarter of 2026. The filing primarily directs investors to a furnished press release (Exhibit 99.1) which contains the detailed financial performance and operational updates for the period. While specific GAAP figures are not detailed in the 8-K text itself, the company emphasizes its use of non-GAAP financial measures. These adjusted figures exclude items such as acquisition-related expenses, stock-based compensation acceleration, restructuring costs, certain regulatory costs, and tax adjustments, aiming to provide a clearer view of ongoing business performance. Management believes these non-GAAP measures offer valuable insights into operational trends, complementing the standard GAAP reporting.
ABBOTT LABORATORIES 8-K Report, Corporate Update (Mar 23, 2026)
Abbott Laboratories (ABT) has announced the successful completion of its acquisition of Exact Sciences Corporation, a significant move that closed on March 23, 2026. This strategic acquisition, executed through a merger agreement finalized on November 19, 2025, integrates Exact Sciences into Abbott's structure as a wholly owned subsidiary. The transaction involved an all-cash payout of $105.00 per share for Exact Sciences common stock, a substantial financial commitment by Abbott. This acquisition is expected to be a transformative event for Abbott, likely bolstering its position in the diagnostics and healthcare markets, particularly in areas where Exact Sciences has a strong presence, such as cancer screening and genomic testing. Investors should closely monitor the integration process and the impact on Abbott's future revenue streams and market share, as this deal represents a major step in the company's growth strategy.
ABBOTT LABORATORIES 8-K Report, Material Agreement (Mar 9, 2026)
Abbott Laboratories (ABT) has announced the successful completion of a significant public offering of senior notes, raising a total of $20 billion. This substantial debt issuance comprises various tranches with different maturities and interest rates, ranging from floating rate notes due in 2029 to fixed-rate notes maturing in 2066. The primary purpose of this financing is to fund the acquisition of Exact Sciences Corporation, a strategic move that underscores Abbott's commitment to expanding its presence in the diagnostics and oncology sectors. While the offering provides the necessary capital for this major acquisition, investors should be aware of the conditional nature of the debt. The indenture includes a special mandatory redemption clause. If the Exact Sciences acquisition does not close by a specified date (currently the later of February 17, 2027, or an agreed-upon later date), or if Abbott decides not to proceed with the acquisition, the company will be obligated to redeem all outstanding notes at a premium (101% of principal plus accrued interest). This structure highlights the importance of the Exact Sciences deal for both Abbott's strategic direction and its financing obligations.
View all 8-K filings →